Hims House Shaun Noorian (Empower Pharmacy CEO) - GLP-1s, Patents, and the Future of Compounding
21 snips
Aug 19, 2025 
Shaun Noorian, the founder and CEO of Empower Pharmacy, leads the world's largest compounding pharmacy, advocating for personalized medicine. He dives into the misconceptions about GLP-1 drugs and the ongoing legal battle against Eli Lilly over tirzepatide patents. The discussion highlights the critical role compounding plays in healthcare, not as a loophole but as a necessary service. Noorian also outlines future trends in hormone therapy and peptides, navigating the complexities of regulations and patient safety in an evolving industry.
AI Snips
Chapters
Transcript
Episode notes
Growth Areas And Legal Limits
- Empower sees growth across HRT, peptides, longevity drugs and sleep therapies as logical expansions.
- Noorian cautions that only FDA-approved peptides can be compounded legally; many experimental peptides remain off-limits.
Use Approved Peptides First
- Use approved growth-hormone-releasing agents like sermorelin under prescription rather than untested peptides.
- Explain to patients that sermorelin mimics GHRH and promotes pituitary release of growth hormone.
Low Odds For Blanket GLP-1 Ban
- Noorian gives a low probability (5%) that FDA will expand new enforcement to ban compounded GLP-1s before 2026.
- He argues there's no legal mechanism to broadly ban compounding of specific approved drugs without changing statute.